Risk stratification for localized #ProstateCancer. Matthew Cooperberg, MD, MPH, FACS UCSF joins Charles Ryan, MD Prostate Cancer Foundation discussing which patients should recieve #ActiveSurveillance and who should not. #WatchNow on UroToday
8 days ago
#Lantheus’ PYLARIFY AI™ Platform demonstrates higher efficiency and consistency while maintaining accuracy for assessment of PSMA imaging in #ProstateCancer. #ReadNow details on UroToday
8 days ago
Treatment and survival differences in patients with urothelial vs nonurothelial bladder & upper tract carcinomas. Jeanny Aragon-Ching, MD Inova Schar Cancer Institute joins Sam Chang, MD, MBA Vanderbilt Health discussing a retrospective review she presented at #GU22
8 days ago
The importance of multidisciplinary collaboration in #Urology clinics. Neal Shore, MD, FACS Atlantic Urology Clinics joins Alicia Morgans, MD, MPH Dana-Farber Cancer Institute to discuss work presented in a plenary presentation at #AUA22
8 days ago
Future targets for cellular therapy in #ProstateCancer. Presentation by Vivek Narayan, MD, MS University of Pennsylvania. #ASCO22 written coverage by Alok Tewari, MD, PhD Dana-Farber Cancer Institute on UroToday
12 days ago
Treatment considerations in advanced #ProstateCancer. Bertrand Tombal, MD, PhD UCLouvain – Université catholique de Louvain joins Alicia Morgans, MD, MPH Dana-Farber Cancer Institute to discuss #ARASENS and #PEACE1 data as well as the messages around maximal androgen blockade and PARP inhibitors
12 days ago
#BrightUro launches with $6 Million in seed financing and grant from the National Institutes of Health (NIH). #PressRelease #ReadNow details on UroToday
12 days ago
Introduction as well as panel question & answer. Presentation by David VanderWeele, MD, PhD Northwestern University Feinberg School of Medicine #ASCO22 written coverage by Alok Tewari, MD, PhD Dana-Farber Cancer Institute
12 days ago
Bispecific T-cell engager (BiTE®) in development for treatment of advanced #ProstateCancer. Oliver Sartor, MD Tulane Cancer Center joins Alicia Morgans, MD, MPH Dana-Farber Cancer Institute to discuss the evolving landscape of BiTE® technology in prostate cancer therapy.
13 days ago
Загрузить еще